1-----------------------------------------------------------
<header><meta http-equiv="Content-Type" content="text/html;charset=UTF-8">
<h1 itemprop="headline name">A-HYDROCORT</h1>
<div class="byline entry-meta lightlinks">By <span itemprop="author" class="author vcard"><abbr class="fn" title="Hospira, Inc.">Hospira, Inc.</abbr></span> | Last revised: 12 May 2011<meta itemprop="datePublished" content="2011-05-12">
</div>
<meta itemprop="image" content="http://medlibrary.org/lib/images-rx/a-hydrocort/a-hydrocort-for-injection-usp1-figure-2-jrl-2526.jpg"></header><meta itemprop="description" content="Hospira, Inc.: When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition. A-Hydrocort sterile powder is indicated for intravenous or intramuscular use...">
<p class="DocumentTitle"><strong>A-HYDROCORT- hydrocortisone sodium succinate injection, powder, lyophilized, for solution</strong><br>Hospira, Inc.<br></p>
<div><a id="section-1"></a></div> <h2><a id="b7a70e7f-3b8a-4f55-8293-b056981ad111"></a></h2>
<p class="First "> <span class="Bold "> <span class="Emphasis ">Hydrocortisone Sodium Succinate</span> </span> </p>
<p> <span class="Bold "> <span class="Emphasis ">for Injection, USP</span> </span> </p>
<p>R<sub>x</sub> only</p>
<p> <span class="Bold "> <span class="Emphasis ">For Intravenous or Intramuscular Administration</span> </span> </p>
<h2>DESCRIPTION<a id="dca14a04-c196-4a27-b333-19909e1ea99e"></a><a id="section-11"></a>
</h2>
<p class="First ">A-Hydrocort sterile powder contains hydrocortisone sodium succinate as the active ingredient. Hydrocortisone sodium succinate, is a white, or nearly white, odorless, hygroscopic, amorphous solid. It is very soluble in water and in alcohol, very slightly soluble in acetone and insoluble in chloroform. The chemical name is pregn-4-ene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11β)- and its molecular weight is 484.52.</p>
<aside id="ab1e" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><p>The structural formula is represented below:</p>
<div class="post_image" style="width:300px"> <div class="post_image_img"> <a href="img/a-hydrocort-for-injection-usp1-figure-1-xen-1768-1-300x171.jpg"><img alt="structural formula hydrocortisone sodium succinate" src="img/a-hydrocort-for-injection-usp1-figure-1-xen-1768-1-300x171.jpg"></a> </div>
<div class="post_image_attr"> <a href="img/a-hydrocort-for-injection-usp1-figure-1-xen-1768-1-300x171.jpg">(click image for full-size original)</a> </div>
</div>
<p>Hydrocortisone sodium succinate is an anti-inflammatory adrenocortical steroid. This highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly.</p>
<p>A-Hydrocort sterile powder is available for intravenous or intramuscular administration.</p>
<p><span class="Bold "><span class="Emphasis ">100 mg</span></span> − Vials containing hydrocortisone sodium succinate equivalent to 100 mg hydrocortisone, also 0.8 mg monobasic sodium phosphate anhydrous, 8.73 mg dibasic sodium phosphate anhydrous.</p>
<p>When necessary, the pH was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8.</p>
<p>For intravenous or intramuscular injection, vial should be reconstituted with Bacteriostatic Water for Injection or Bacteriostatic Sodium Chloride. </p>
<p>For intravenous infusion, vial should be reconstituted with Bacteriostatic Water for Injection.</p>
<h2>CLINICAL PHARMACOLOGY<a id="a9a365c4-1b09-4676-b397-2d5afeddf817"></a><a id="section-12"></a>
</h2>
<p class="First ">Hydrocortisone sodium succinate has the same metabolic
and anti-inflammatory actions as hydrocortisone. When given parenterally
and in equimolar quantities, the two compounds are equivalent in biologic
activity. Following the intravenous injection of hydrocortisone sodium
succinate, demonstrable effects are evident within one hour and persist
for a variable period. Excretion of the administered dose is nearly
complete within 12 hours. Thus, if constantly high blood levels are
required, injections should be made every 4 to 6 hours. This preparation
is also rapidly absorbed when administered intramuscularly and is
excreted in a pattern similar to that observed after intravenous injection.<br></p>
<h2>INDICATIONS AND USAGE<a id="a9343f38-94b3-4ad9-9925-b94f0897dc22"></a>
</h2>
<aside id="ab2e" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><p class="First ">When oral therapy is not feasible, and the strength,
dosage form and route of administration of the drug reasonably lend
the preparation to the treatment of the condition, A-Hydrocort sterile
powder is indicated for intravenous or intramuscular use in the following
conditions: </p>
<p> <span class="Bold "> <span class="Emphasis ">1. Endocrine
Disorders</span> </span> </p>
<ul>
<li> <p class="First ">Primary or secondary adrenocortical insufficiency
(hydrocortisone or cortisone is the drug of choice; synthetic analogs
may be used in conjunction with mineralocorticoids where applicable;
in infancy, mineralocorticoid supplementation is of particular importance)</p>
</li> <li> <p class="First ">Acute adrenocortical insufficiency (hydrocortisone
or cortisone is the drug of choice; mineralocorticoid supplementation
may be necessary, particularly when synthetic analogs are used)</p>
</li> <li> <p class="First ">Preoperatively and in the event of serious trauma
or illness, in patients with known adrenal insufficiency or when adrenocortical
reserve is doubtful</p>
</li> <li> <p class="First ">Shock unresponsive to conventional therapy if adrenocortical
insufficiency exists or is suspected</p>
</li> <li> <p class="First ">Congenital adrenal hyperplasia</p>
</li> <li> <p class="First ">Hypercalcemia associated with cancer</p>
</li> <li> <p class="First ">Nonsuppurative thyroiditis</p>
</li> </ul>
<br><p> <span class="Bold "> <span class="Emphasis ">2. Rheumatic Disorders</span> </span> </p>
<p>As adjunctive therapy for short-term
administration (to tide the patient over an acute episode or exacerbation)
in:</p>
<ul>
<li> <p class="First ">Post-traumatic osteoarthritis</p>
</li> <li> <p class="First ">Synovitis of osteoarthritis</p>
</li> <li> <p class="First ">Rheumatoid arthritis, including juvenile rheumatoid
arthritis (selected cases may require low-dose maintenance therapy)</p>
</li> <li> <p class="First ">Acute and subacute bursitis</p>
</li> <li> <p class="First ">Epicondylitis</p>
</li> <li> <p class="First ">Acute nonspecific tenosynovitis</p>
</li> <li> <p class="First ">Acute gouty arthritis</p>
</li> <li> <p class="First ">Psoriatic arthritis</p>
</li> <li> <p class="First ">Ankylosing spondylitis</p>
</li> </ul>
<p> <span class="Bold "> <span class="Emphasis ">3. Collagen Diseases</span> </span> </p>
<p>During an exacerbation or as maintenance
therapy in selected cases of:</p>
<ul>
<li> <p class="First ">Systemic lupus erythematosus</p>
</li> <li> <p class="First ">Systemic dermatomyositis (polymyositis)</p>
</li> <li> <p class="First ">Acute rheumatic carditis</p>
</li> </ul>
<br><p> <span class="Bold "> <span class="Emphasis ">4. Dermatologic Diseases</span> </span> </p>
<ul>
<li> <p class="First ">Pemphigus</p>
</li> <li> <p class="First "> Severe erythema multiforme (Stevens-Johnson syndrome)</p>
</li> <li> <p class="First ">Exfoliative dermatitis</p>
</li> <li> <p class="First ">Bullous dermatitis herpetiformis</p>
</li> <li> <p class="First ">Severe seborrheic dermatitis</p>
</li> <li> <p class="First "> Severe psoriasis</p>
</li> <li> <p class="First ">Mycosis fungoides</p>
</li> </ul>
<br><p> <span class="Bold "> <span class="Emphasis ">5. Allergic States </span> </span> </p>
<p>Control of severe or incapacitating allergic
conditions intractable to adequate trials of conventional treatment
in: </p>
<ul>
<li> <p class="First ">Bronchial asthma</p>
</li> <li> <p class="First ">Contact dermatitis</p>
</li> <li> <p class="First ">Atopic dermatitis</p>
</li> <li> <p class="First ">Serum sickness</p>
</li> <li> <p class="First ">Seasonal or perennial allergic rhinitis</p>
</li> <li> <p class="First ">Drug hypersensitivity reactions</p>
</li> <li> <p class="First ">Urticarial transfusion reactions</p>
</li> <li> <p class="First ">Acute noninfectious laryngeal edema (epinephrine
is the drug of first choice)</p>
</li> </ul>
<br><p> <span class="Bold "> <span class="Emphasis ">6. Ophthalmic Diseases</span> </span> </p>
<p>Severe acute and chronic allergic and
inflammatory processes involving the eye, such as: </p>
<ul>
<li> <p class="First ">Herpes zoster ophthalmicus</p>
</li> <li> <p class="First ">Iritis, iridocyclitis</p>
</li> <li> <p class="First "> Chorioretinitis</p>
</li> <li> <p class="First ">Diffuse posterior uveitis and choroiditis</p>
</li> <li> <p class="First ">Optic neuritis</p>
</li> <li> <p class="First ">Sympathetic ophthalmia</p>
</li> <li> <p class="First ">Anterior segment inflammation</p>
</li> <li> <p class="First ">Allergic conjunctivitis</p>
</li> <li> <p class="First "> Allergic corneal marginal ulcers</p>
</li> <li> <p class="First "> Keratitis</p>
</li> </ul>
<br><p> <span class="Bold "> <span class="Emphasis ">7. Gastrointestinal
Diseases</span> </span> </p>
<p>To tide the patient
over a critical period of the disease in:</p>
<ul>
<li> <p class="First ">Ulcerative colitis (systemic therapy)</p>
</li> <li> <p class="First ">Regional enteritis (systemic therapy)</p>
</li> </ul>
<br><p> <span class="Bold "> <span class="Emphasis ">8. Respiratory Diseases </span> </span> </p>
<ul>
<li> <p class="First ">Symptomatic sarcoidosis</p>
</li> <li> <p class="First ">Berylliosis</p>
</li> <li> <p class="First "> Fulminating or disseminated pulmonary tuberculosis
when used concurrently with appropriate antituberculous chemotherapy</p>
</li> <li> <p class="First ">Loeffler’s syndrome not manageable by other
means </p>
</li> <li> <p class="First ">Aspiration pneumonitis</p>
</li> </ul>
<p> <span class="Bold "> <span class="Emphasis ">9. Hematologic Disorders</span> </span> <br></p>
<ul>
<li> <p class="First ">Acquired (autoimmune) hemolytic anemia</p>
</li> <li> <p class="First ">Idiopathic thrombocytopenic purpura in adults (IV
only; IM administration is contraindicated)</p>
</li> <li> <p class="First ">Secondary thrombocytopenia in adults</p>
</li> <li> <p class="First ">Erythroblastopenia (RBC anemia)</p>
</li> <li> <p class="First ">Congenital (erythroid) hypoplastic anemia</p>
</li> </ul>
<p> <span class="Bold "> <span class="Emphasis ">10. Neoplastic Diseases</span> </span> </p>
<p>For palliative management of: </p>
<ul>
<li> <p class="First ">Leukemias and lymphomas in adults</p>
</li> <li> <p class="First ">Acute leukemia of childhood</p>
</li> </ul>
<p> <span class="Bold "> <span class="Emphasis ">11. Edematous States</span> </span> </p>
<p>To induce diuresis or remission of proteinuria
in the nephrotic syndrome, without uremia, of the idiopathic type
or that due to lupus erythematosus</p>
<p> <span class="Bold "> <span class="Emphasis ">12. Nervous System</span> </span> </p>
<p>Acute exacerbations of multiple sclerosis</p>
<p> <span class="Bold "> <span class="Emphasis ">13. Miscellaneous </span> </span> </p>
<ul>
<li> <p class="First ">Tuberculous meningitis with subarachnoid block or
impending block when used concurrently with appropriate antituberculous
chemotherapy</p>
</li> <li> <p class="First "> Trichinosis with neurologic or myocardial involvement</p>
</li> </ul>
<footer><div class="wp-pagenavi">
<span class="pages">Page 1 of 3</span>  <span class="current">1</span>  <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/page/2/" class="page larger">2</a> <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/page/3/" class="page larger">3</a> <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/page/2/">»</a> </div>
<aside id="abre" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><div class="reviewnote lightlinks">
<p>All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.</p>
<p>The URL of this page is:<br><a href="http://medlibrary.org/lib/rx/meds/a-hydrocort/" rel="bookmark">http://medlibrary.org/lib/rx/meds/a-hydrocort/</a></p>
</div>
</footer>
2-----------------------------------------------------------<article><header><meta http-equiv="Content-Type" content="text/html;charset=UTF-8">
<h1 itemprop="headline name">A-HYDROCORT (Page 2 of 3)</h1>
<div class="byline entry-meta lightlinks">By <span itemprop="author" class="author vcard"><abbr class="fn" title="Hospira, Inc.">Hospira, Inc.</abbr></span> | Last revised: 12 May 2011<meta itemprop="datePublished" content="2011-05-12">
</div>
<meta itemprop="image" content="http://medlibrary.org/lib/images-rx/a-hydrocort/a-hydrocort-for-injection-usp1-figure-2-jrl-2526.jpg"></header><meta itemprop="description" content="Page 2: Hospira, Inc.: When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition. A-Hydrocort sterile powder is indicated for intravenous or intramuscular use...">
<h2>CONTRAINDICATIONS<a id="c1bd2fd6-2622-4e1e-9b88-561b49d6fb17"></a><a id="section-4"></a>
</h2>
<p class="First ">The use of A-Hydrocort sterile powder is contraindicated
in premature infants because the 100 mg vial is reconstituted with
Bacteriostatic Water for Injection or Bacteriostatic Sodium Chloride
Injection containing benzyl alcohol. Benzyl alcohol has been reported
to be associated with a fatal “Gasping Syndrome” in
premature infants. A-Hydrocort sterile powder is also contraindicated
in systemic fungal infections and patients with known hypersensitivity
to the product and its constituents. </p>
<h2>WARNINGS<a id="d5131c88-10b1-453d-bcb2-fef7d35a4f3d"></a><a id="section-6"></a>
</h2>
<p class="First ">In patients on corticosteroid therapy subjected to
unusual stress, increased dosage of rapidly acting corticosteroids
before, during, and after the stressful situation is indicated. </p>
<aside id="ab1e" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><p>Corticosteroids may mask some signs of infection, and
new infections may appear during their use. There may be decreased
resistance and inability to localize infection when corticosteroids
are used. </p>
<p>Prolonged use of corticosteroids
may produce posterior subcapsular cataracts, glaucoma with possible
damage to the optic nerves, and may enhance the establishment of secondary
ocular infections due to fungi or viruses.</p>
<p><span class="Italics "><span class="Emphasis ">Usage in pregnancy</span></span>. Since adequate human
reproduction studies have not been done with corticosteroids, the
use of these drugs in pregnancy, nursing mothers, or women of childbearing
potential requires that the possible benefits of the drug be weighed
against the potential hazards to the mother and embryo or fetus. Infants
born of mothers who have received substantial doses of corticosteroids
during pregnancy should be carefully observed for signs of hypoadrenalism. </p>
<p>Average and large doses of hydrocortisone can cause elevation
of blood pressure, salt and water retention, and increased excretion
of potassium. These effects are less likely to occur with the synthetic
derivatives except when used in large doses. Dietary salt restriction
and potassium supplementation may be necessary. All corticosteroids
increase calcium excretion. </p>
<p> <span class="Bold "> <span class="Emphasis ">While on corticosteroid therapy patients should not
be vaccinated against smallpox. Other immunization procedures should
not be undertaken in patients who are on corticosteroids, especially
on high dose, because of possible hazards of neurological complications
and a lack of antibody response.</span> </span> </p>
<p>The
use of A-Hydrocort sterile powder in active tuberculosis should be
restricted to those cases of fulminating or disseminated tuberculosis
in which the corticosteroid is used for the management of the disease
in conjunction with appropriate antituberculous regimen. </p>
<p>If corticosteroids are indicated in patients with latent
tuberculosis or tuberculin reactivity, close observation is necessary
as reactivation of the disease may occur. During prolonged corticosteroid
therapy, these patients should receive chemoprophylaxis. </p>
<p>Because rare instances of anaphylactoid reactions (eg,
bronchospasm) have occurred in patients receiving parenteral corticosteroid
therapy, appropriate precautionary measures should be taken prior
to administration, especially when the patient has a history of allergy
to any drug. </p>
<aside id="ab2e" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><p>Persons who are on drugs which
suppress the immune system are more susceptible to infections than
healthy individuals. Chicken pox and measles, for example, can have
a more serious or even fatal course in non-immune children or adults
on corticosteroids. In such children or adults who have not had these
diseases, particular care should be taken to avoid exposure. How the
dose, route and duration of corticosteroid administration affects
the risk of developing a disseminated infection is not known. The
contribution of the underlying disease and/or prior corticosteroid
treatment to the risk is also not known. If exposed to chicken pox,
prophylaxis with varicella zoster immune globulin (VZIG) may be indicated.
If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin
(IG) may be indicated. (See the respective package inserts for complete
VZIG and IG prescribing information.) If chicken pox develops, treatment
with antiviral agents may be considered. </p>
<h2>PRECAUTIONS<a id="d4c80493-ddee-46ea-9e23-2904336c25d8"></a><a id="section-7"></a>
</h2> <h3>General Precautions<a id="f2cd6ff6-9695-49b1-b1f7-1e9c5b9a15f0"></a><a id="section-7.1"></a>
</h3> <p class="First ">Drug-induced secondary adrenocortical insufficiency
may be minimized by gradual reduction of dosage. This type of relative
insufficiency may persist for months after discontinuation of therapy;
therefore, in any situation of stress occurring during that period,
hormone therapy should be reinstituted. Since mineralocorticoid secretion
may be impaired, salt and/or a mineralocorticoid should be administered
concurrently. </p>
<p>There is an enhanced effect of
corticosteroids in patients with hypothyroidism and in those with
cirrhosis.</p>
<p>Corticosteroids should be used cautiously
in patients with ocular herpes simplex for fear of corneal perforation. </p>
<p>The lowest possible dose of corticosteroid should be used
to control the condition under treatment, and when reduction in dosage
is possible, the reduction must be gradual.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging
from euphoria, insomnia, mood swings, personality changes, and severe
depression, to frank psychotic manifestations. Also, existing emotional
instability or psychotic tendencies may be aggravated by corticosteroids.</p>
<p>Aspirin should be used cautiously in conjunction with
corticosteroids in hypoprothrombinemia.</p>
<p>Steroids
should be used with caution in nonspecific ulcerative colitis, if
there is a probability of impending perforation, abscess or other
pyogenic infection, also in diverticulitis, fresh intestinal anastomoses,
active or latent peptic ulcer, renal insufficiency, hypertension,
osteoporosis, and myasthenia gravis. </p>
<p>Growth
and development of infants and children on prolonged corticosteroid
therapy should be carefully followed.</p>
<p>Although
controlled clinical trials have shown corticosteroids to be effective
in speeding the resolution of acute exacerbations of multiple sclerosis,
they do not show that corticosteroids affect the ultimate outcome
or natural history of the disease. The studies do show that relatively
high doses of corticosteroids are necessary to demonstrate a significant
effect. (See <span class="Bold Italics "><span class="Emphasis ">DOSAGE AND ADMINISTRATION</span></span>).</p>
<p>Since complications of treatment with glucocorticoids are dependent
on the size of the dose and duration of treatment, a risk/benefit
decision must be made in each individual case as to dose and duration
of treatment and as to whether daily or intermittent therapy should
be used. </p>
<h2>DRUG INTERACTIONS<a id="a85301c5-6311-4e9b-b4cd-d9cb27256fdf"></a>
</h2>
<p class="First ">The pharmacokinetic interactions listed below are
potentially clinically important. Drugs that induce hepatic enzymes
such as phenobarbital, phenytoin and rifampin may increase the clearance
of corticosteroids and may require increases in corticosteroid dose
to achieve the desired response. Drugs such as troleandomycin and
ketoconazole may inhibit the metabolism of corticosteroids and thus
decrease their clearance. Therefore, the dose of corticosteroid should
be titrated to avoid steroid toxicity. Corticosteroids may increase
the clearance of chronic high-dose aspirin. This could lead to decreased
salicylate serum levels or increase the risk of salicylate toxicity
when corticosteroid is withdrawn. Aspirin should be used cautiously
in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
The effect of corticosteroids on oral anticoagulants is variable.
There are reports of enhanced as well as diminished effects of anticoagulants
when given concurrently with corticosteroids. Therefore, coagulation
indices should be monitored to maintain the desired anticoagulant
effect. </p>
<h3>Information for the Patient<a id="d2dde88b-b5ba-4103-b4f5-0d9c8843e1b3"></a><a id="section-7.17"></a>
</h3> <p class="First ">Persons who are on immunosuppressant doses of corticosteroids
should be warned to avoid exposure to chicken pox or measles. Patients
should also be advised that if they are exposed, medical advice should
be sought without delay. </p>
<h2>ADVERSE REACTIONS<a id="bf3a68a7-4476-4f12-a4b0-e1e5d479342d"></a>
</h2>
<p class="First "> <span class="Bold "> <span class="Emphasis ">Fluid and Electrolyte Disturbances </span> </span> </p>
<p>Sodium retention, Fluid retention, Congestive
heart failure in susceptible patients, Potassium loss, Hypokalemic
alkalosis, Hypertension</p>
<p> <span class="Bold "> <span class="Emphasis ">Musculoskeletal </span> </span> </p>
<p>Muscle weakness,
Steroid myopathy, Loss of muscle mass, Osteoporosis, Vertebral compression
fractures, Aseptic necrosis of femoral and humeral heads, Pathologic
fracture of long bones</p>
<p> <span class="Bold "> <span class="Emphasis ">Gastrointestinal</span> </span> </p>
<p>Peptic ulcer with
possible perforation and hemorrhage, Pancreatitis, Abdominal distention,
Ulcerative esophagitis</p>
<p> <span class="Bold "> <span class="Emphasis ">Dermatologic </span> </span> </p>
<p>Impaired wound healing,
Thin fragile skin, Petechiae and ecchymoses, Facial erythema, Increased
sweating, May suppress reactions to skin tests</p>
<p> <span class="Bold "> <span class="Emphasis ">Neurological </span> </span> </p>
<p>Convulsions, Increased intracranial pressure with papilledema (pseudotumor
cerebri) usually after treatment, Vertigo, Headache</p>
<p> <span class="Bold "> <span class="Emphasis ">Endocrine</span> </span> </p>
<p>Menstrual irregularities, Development of Cushingoid state, Suppression
of growth in children, Secondary adrenocortical and pituitary unresponsiveness,
particularly in times of stress, as in trauma, surgery, or illness,
Decreased carbohydrate tolerance, Manifestations of latent diabetes
mellitus, Increased requirements of insulin or oral hypoglycemic agents
in diabetics</p>
<p> <span class="Bold "> <span class="Emphasis ">Ophthalmic </span> </span> </p>
<p>Posterior subcapsular cataracts, Increased
intraocular pressure, Glaucoma, Exophthalmos</p>
<p> <span class="Bold "> <span class="Emphasis ">Metabolic</span> </span> </p>
<p>Negative nitrogen balance due to protein catabolism </p>
<p>The following additional reactions are related to parenteral corticosteroid
therapy: </p>
<p>Allergic, anaphylactic or other hypersensitivity
reactions, Hyperpigmentation or hypopigmentation, Subcutaneous and
cutaneous atrophy, Sterile abscess</p>

<footer><div class="wp-pagenavi">
<span class="pages">Page 2 of 3</span>  <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/">«</a> <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/" class="page smaller">1</a> <span class="current">2</span>  <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/page/3/" class="page larger">3</a> <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/page/3/">»</a> </div>
<aside id="abre" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><div class="reviewnote lightlinks">
<p>All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.</p>
<p>The URL of this page is:<br><a href="http://medlibrary.org/lib/rx/meds/a-hydrocort/page/2/" rel="bookmark">http://medlibrary.org/lib/rx/meds/a-hydrocort/page/2/</a></p>
</div>
</footer></article>3-----------------------------------------------------------
<header><meta http-equiv="Content-Type" content="text/html;charset=UTF-8">
<h1 itemprop="headline name">A-HYDROCORT (Page 3 of 3)</h1>
<div class="byline entry-meta lightlinks">By <span itemprop="author" class="author vcard"><abbr class="fn" title="Hospira, Inc.">Hospira, Inc.</abbr></span> | Last revised: 12 May 2011<meta itemprop="datePublished" content="2011-05-12">
</div>
<meta itemprop="image" content="http://medlibrary.org/lib/images-rx/a-hydrocort/a-hydrocort-for-injection-usp1-figure-2-jrl-2526.jpg"></header><meta itemprop="description" content="Page 3: Hospira, Inc.: When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition. A-Hydrocort sterile powder is indicated for intravenous or intramuscular use...">
<h2>DOSAGE AND ADMINISTRATION<a id="c81fd9af-85b3-40ce-9abb-30d36c6b6a16"></a><a id="section-2"></a>
</h2>
<p class="First ">This preparation may be administered by intravenous
injection, by intravenous infusion, or by intramuscular injection,
the preferred method for initial emergency use being intravenous injection.
Following the initial emergency period, consideration should be given
to employing a longer acting injectable preparation or an oral preparation. </p>
<p>Therapy is initiated by administering A-Hydrocort sterile
powder intravenously over a period of 30 seconds (eg, 100 mg) to 10
minutes (eg, 500 mg or more). In general, high-dose corticosteroid
therapy should be continued only until the patient’s condition
has stabilized − usually not beyond 48 to 72 hours. Although
adverse effects associated with high-dose, short-term corticoid therapy
are uncommon, peptic ulceration may occur. Prophylactic antacid therapy
may be indicated.</p>
<aside id="ab1e" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><p>When high-dose hydrocortisone
therapy must be continued beyond 48-72 hours, hypernatremia may occur.
Under such circumstances it may be desirable to replace hydrocortisone
sodium succinate with a corticoid such as methylprednisolone sodium
succinate which causes little or no sodium retention.</p>
<p>The initial dose of A-Hydrocort sterile powder is 100 mg to 500 mg,
depending on the severity of the condition. This dose may be repeated
at intervals of 2, 4 or 6 hours as indicated by the patient’s
response and clinical condition. While the dose may be reduced for
infants and children, it is governed more by the severity of the condition
and response of the patient than by age or body weight but should
not be less than 25 mg daily. </p>
<p>Patients subjected
to severe stress following corticosteroid therapy should be observed
closely for signs and symptoms of adrenocortical insufficiency. </p>
<p>Corticoid therapy is an adjunct to, and not a replacement
for, conventional therapy.</p>
<p> <span class="Bold "> <span class="Emphasis ">Preparation of Solutions</span> </span> </p>
<p><span class="Bold "><span class="Emphasis ">100 mg </span></span>− For intravenous
or intramuscular injection, prepare solution by aseptically adding <span class="Bold "><span class="Emphasis ">not more than 2 mL</span></span> of Bacteriostatic Water
for Injection or Bacteriostatic Sodium Chloride Injection to the contents
of one vial. <span class="Bold "><span class="Emphasis ">Further dilution is not necessary
for intravenous or intramuscular</span></span><span class="Bold "><span class="Emphasis "> injection.  For intravenous infusion,</span></span> first prepare solution
by adding <span class="Bold "><span class="Emphasis ">not more than 2 mL</span></span> of
Bacteriostatic Water for Injection to the vial; this solution may
then be added to 100 to 1000 mL of the following: 5% dextrose in water
(or isotonic saline solution or 5% dextrose in isotonic saline solution
if patient is not on sodium restriction). In cases where administration
of a small volume of fluid is desirable, 100 mg of hydrocortisone
sodium succinate may be added to 50 mL of the above diluents. The
resulting solutions are stable for at least 4 hours and may be administered
either directly or by IV piggyback.</p>
<p>When reconstituted
as directed, pH’s of the solutions range from 7 to 8 and the
tonicities are: 100 mg vial, .36 osmolar. (Isotonic saline = .28 osmolar.)</p>
<h2>HOW SUPPLIED<a id="c00d2827-c2f3-4623-a74f-23e6d3006f43"></a><a id="section-16"></a>
</h2>
<aside id="ab2e" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><p class="First ">A-Hydrocort sterile powder is available in the following package:</p>
<table style="width:auto; max-width:99% !important;"><tbody class="Headless ">
<tr class="First ">
<td class="Botrule Lrule Rrule Toprule "> <p class="First "> <span class="Bold "> <span class="Emphasis ">NDC</span> </span> </p>
</td> <td class="Botrule Lrule Rrule Toprule "> <p class="First "> <span class="Bold "> <span class="Emphasis ">Container </span> </span> </p>
</td> <td class="Botrule Lrule Rrule Toprule "> <p class="First "> <span class="Bold "> <span class="Emphasis ">Concentration </span> </span> </p>
</td> </tr>
<tr class="Last ">
<td class="Botrule Lrule Rrule Toprule "> <p class="First ">0409-4856-15</p>
</td> <td class="Botrule Lrule Rrule Toprule ">Single-Dose Vial</td> <td class="Botrule Lrule Rrule Toprule "> <p class="First ">100 mg</p>
</td> </tr>
</tbody></table>
<p> <span class="Bold "> <span class="Emphasis ">STORAGE CONDITIONS</span> </span> </p>
<p>Store unreconstituted product at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]</p>
<p>Store solution at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from light.</p>
<p>Use solution only if it is clear. Unused solution should be discarded after 3 days.</p>
<p>Lyophilized in container.</p>
<p>Revised: April, 2008</p>
<table style="width:auto; max-width:99% !important;"><tbody class="Headless ">
<tr class="First ">
<td class="Botrule Lrule Rrule Toprule "> <p class="First ">Printed in USA</p>
</td> <td class="Botrule Lrule Rrule Toprule " colspan="2" style="text-align:center"> <p class="First ">EN-1768</p>
</td> </tr>
<tr class="Last ">
<td class="Botrule Lrule Rrule Toprule " colspan="3"> <p class="First ">Hospira, Inc., Lake Forest, IL 60045 USA</p>
</td> </tr>
</tbody></table>
<h2>RL-2526<a id="e632e32d-561d-483e-bff8-af8351c6ce04"></a>
</h2>
<div class="post_image" style="width:300px"> <div class="post_image_img"> <a href="img/a-hydrocort-for-injection-usp1-figure-2-jrl-2526-300x99.jpg"><img alt="label ndc 0409-4856-15" src="img/a-hydrocort-for-injection-usp1-figure-2-jrl-2526-300x99.jpg"></a> </div>
<div class="post_image_attr"> <a href="img/a-hydrocort-for-injection-usp1-figure-2-jrl-2526-300x99.jpg">(click image for full-size original)</a> </div>
</div>
<table class="contentTablePetite" cellspacing="0" cellpadding="3" width="100%"><tbody>
<tr>
<td class="contentTableTitle"> <strong>A-HYDROCORT</strong> <br><span class="contentTableReg">hydrocortisone sodium succinate injection, powder, lyophilized, for solution</span> </td> </tr>
<tr>
<td> <table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr>
<td colspan="4" class="formHeadingTitle">Product Information</td> </tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td> <td class="formItem">HUMAN PRESCRIPTION DRUG</td> <td class="formLabel">Item Code (Source)</td> <td class="formItem">NDC:0409-4856</td> </tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td> <td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td> <td width="30%" class="formLabel">DEA Schedule</td> <td class="formItem"> </td> </tr>
</table>
</td> </tr>
<tr>
<td> <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr>
<td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td> </tr>
<tr>
<td class="formTitle">Ingredient Name</td> <td class="formTitle">Basis of Strength</td> <td class="formTitle">Strength</td> </tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE SODIUM SUCCINATE</strong> (HYDROCORTISONE) </td> <td class="formItem">HYDROCORTISONE SODIUM SUCCINATE</td> <td class="formItem">100 mg  in 2 mL</td> </tr>
</table>
</td> </tr>
<tr>
<td> <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr>
<td colspan="2" class="formHeadingTitle">Inactive Ingredients</td> </tr>
<tr>
<td class="formTitle">Ingredient Name</td> <td class="formTitle">Strength</td> </tr>
<tr class="formTableRowAlt">
<td class="formItem"> <strong>SODIUM PHOSPHATE, MONOBASIC ANHYDROUS</strong> </td> <td class="formItem">0.8 mg  in 2 mL</td> </tr>
<tr class="formTableRow">
<td class="formItem"> <strong>SODIUM PHOSPHATE, DIBASIC ANHYDROUS</strong> </td> <td class="formItem">8.73 mg  in 2 mL</td> </tr>
<tr class="formTableRowAlt">
<td class="formItem"> <strong>SODIUM HYDROXIDE</strong> </td> <td class="formItem"> </td> </tr>
</table>
</td> </tr>
<tr>
<td></td> </tr>
<tr>
<td> <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr>
<td colspan="5" class="formHeadingTitle">Packaging</td> </tr>
<tr>
<td width="1" class="formTitle">#</td> <td class="formTitle">Item Code</td> <td class="formTitle">Package Description</td> <td class="formTitle">Multilevel Packaging</td> </tr>
<tr class="formTableRowAlt">
<td class="formItem"> <strong>1</strong> </td> <td class="formItem">NDC:0409-4856-05</td> <td class="formItem">10 VIAL, SINGLE-DOSE (10 VIAL)  in 1 CARTON</td> <td class="formItem">contains a VIAL, SINGLE-DOSE</td> </tr>
<tr class="formTableRowAlt">
<td class="formItem"> <strong>1</strong> </td> <td class="formItem"></td> <td class="formItem">2 mL in 1 VIAL, SINGLE-DOSE</td> <td class="formItem">This package is contained within the CARTON (0409-4856-05)</td> </tr>
<tr class="formTableRow">
<td class="formItem"> <strong>2</strong> </td> <td class="formItem">NDC:0409-4856-15</td> <td class="formItem">25 VIAL, SINGLE-DOSE (25 VIAL)  in 1 TRAY</td> <td class="formItem">contains a VIAL, SINGLE-DOSE</td> </tr>
<tr class="formTableRow">
<td class="formItem"> <strong>2</strong> </td> <td class="formItem"></td> <td class="formItem">2 mL in 1 VIAL, SINGLE-DOSE</td> <td class="formItem">This package is contained within the TRAY (0409-4856-15)</td> </tr>
</table>
</td> </tr>
<tr>
<td></td> </tr>
<tr>
<td class="normalizer"> <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr>
<td colspan="4" class="formHeadingReg"> <span class="formHeadingTitle">Marketing Information</span> </td> </tr>
<tr>
<td class="formTitle">Marketing Category</td> <td class="formTitle">Application Number or Monograph Citation</td> <td class="formTitle">Marketing Start Date</td> <td class="formTitle">Marketing End Date</td> </tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td> <td class="formItem">ANDA040666</td> <td class="formItem">05/12/2011</td> <td class="formItem"></td> </tr>
</table>
</td> </tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr>
<td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler — </span>Hospira, Inc.
       (141588017)
    </td> </tr></table>
<p><span class="EffectiveDate">Revised: 05/2011</span> <span class="DistributorName">Hospira, Inc.</span></p>

<footer><div class="wp-pagenavi">
<span class="pages">Page 3 of 3</span>  <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/page/2/">«</a> <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/" class="page smaller">1</a> <a href="//medlibrary.org/lib/rx/meds/a-hydrocort/page/2/" class="page smaller">2</a> <span class="current">3</span>  </div>
<aside id="abre" style="display:none"><ins class="adsbygoogle" data-ad-client="ca-pub-3862246084592963"></ins>
</aside><div class="reviewnote lightlinks">
<p>All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.</p>
<p>The URL of this page is:<br><a href="http://medlibrary.org/lib/rx/meds/a-hydrocort/page/3/" rel="bookmark">http://medlibrary.org/lib/rx/meds/a-hydrocort/page/3/</a></p>
</div>
</footer>
4-----------------------------------------------------------